Search
Flibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalFlibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. … in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Cefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigational[L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available. … [FDA Label] Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels.
Categories: Compounds used in a research, industrial, or household settingCrotamiton
go.drugbank.com/drugs/DB00265ApprovedIt is miscible with alcohol and with methanol. … Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor.
Categories: Compounds used in a research, industrial, or household settingDaprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigational[A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. … [A254157] A phase 3 clinical trial (NCT02879305) found that in patients with CKD undergoing dialysis, daprodustat was non-inferior to erythropoiesis-stimulating agents regarding the change in the hemoglobin
Synonyms: Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-Tolfenamic acid
go.drugbank.com/drugs/DB09216Approved[A31824] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam. … [L1292] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291]
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigational[L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788] … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.
Viltolarsen
go.drugbank.com/drugs/DB15005ApprovedInvestigationalis contingent on further verification in confirmatory trials. … [A218176] Viltolarsen was granted accelerated FDA approval on August 12, 2020, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with viltolarsen; this approval
Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] In pre- or peri-menopausal women and in men, camizestrant plus a CDK4/6 inhibitor is combined with an LHRH agonist or antagonist. … [L64117] Camizestrant is also approved in Japan, the United Arab Emirates, and Saudi Arabia.[L64117]
Synonyms: 3-pyridinamine, n-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamineAnthralin
go.drugbank.com/drugs/DB11157ApprovedAnthralin is also known as dithranol. It is a main active ingredient in topical skin formulations for the treatment of psoriasis. … It is important to consider that the drug is relatively innocuous, yet effective, and systemic side effects have not been observed with this anthralin, in contrast to a wide variety of systemic and topical
Viloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnIt was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. … Viloxazine is a selective norepinephrine reuptake inhibitor.[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant.